Novel antibodies directed against the human erythropoietin receptor: Creating a basis for clinical implementation

British Journal of Haematology

Volumn 168, Issue 3, 2015, Pages 429-442

  Maxwell, Perry ^a   Melendez Rodríguez, Florinda ^b   Matchett, Kyle B ^a   Aragones, Julian ^b   Ben Califa, Nathalie ^c   Jaekel, Heidelinde ^d   Hengst, Ludger ^d   Lindner, Herbert ^d   Bernardini, Andre ^e   Brockmeier, Ulf ^e   Fandrey, Joachim ^e   Grunert, Fritz ^f   Oster, Howard S ^c   Mittelman, Moshe ^c   El Tanani, Mohamed ^a   Thiersch, Markus ^g   Schneider Gasser, Edith M ^g   Gassmann, Max ^g,h   Dangoor, David ⁱ   Cuthbert, Robert J ^j   Irvine, Alexandra ^a   Jordan, Anne ^a   Lappin, Terence ^a   Thompson, John ^f   Neumann, Drorit ^c   more..

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^b HOSPITAL UNIVERSITARIO SANTA CRISTINA   (Spain)

^c TEL AVIV UNIVERSITY   (Israel)

^d INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^e UNIVERSITY OF DUISBURG ESSEN   (Germany)

^f Aldevron Freiburg GmbH   (Germany)

^g UNIVERSITY OF ZURICH   (Switzerland)

^h UNIVERSIDAD PERUANA CAYETANO HEREDIA   (Peru)

ⁱ OSM DAN Ltd   (Israel)

^j ROYAL GROUP OF HOSPITALS TRUST   (United Kingdom)

more..

Author keywords

Antibody; Cancer anaemia; Erythropoietin receptor; Recombinant erythropoietin; Risk assessment

Indexed keywords

ERYTHROPOIETIN RECEPTOR; GLYCOPHORIN C; JANUS KINASE 2; MESSENGER RNA; MONOCLONAL ANTIBODY; RECOMBINANT ERYTHROPOIETIN; STAT5 PROTEIN; TUMOR PROTEIN;

AMINO ACID SEQUENCE; ANEMIA; ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BONE MARROW BIOPSY; CANCER CELL LINE; CANCER GROWTH; CANCER IMMUNIZATION; CANCER PATIENT; DRUG MEGADOSE; FLOW CYTOMETRY; FLUORESCENCE ACTIVATED CELL SORTING; GENETIC IMMUNIZATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNE RESPONSE; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; IMMUNOREACTIVITY; MASS SPECTROMETRY; NONHUMAN; PLEIOTROPY; PROTEIN DOMAIN; RECEPTOR BINDING; RISK ASSESSMENT; SIGNAL TRANSDUCTION; TUMOR GROWTH; WESTERN BLOTTING; ANIMAL; BIOSYNTHESIS; FLUORESCENT ANTIBODY TECHNIQUE; GENE SILENCING; GENETICS; IMMUNOLOGY; METABOLISM; MOLECULAR GENETICS; MOUSE; NOMENCLATURE; PROCEDURES; RAT; SYNTHESIS; TUMOR CELL CULTURE;

AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, MONOCLONAL; CHEMISTRY TECHNIQUES, SYNTHETIC; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE; GENE SILENCING; HUMANS; IMMUNOPRECIPITATION; MICE; MOLECULAR SEQUENCE DATA; NEOPLASM PROTEINS; RATS; RECEPTORS, ERYTHROPOIETIN; RISK ASSESSMENT; TERMINOLOGY AS TOPIC; TUMOR CELLS, CULTURED;

EID: 84921433708     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.13133     Document Type: Article

References (34)

1. Abramsson, A., Lindblom, P. & Betsholtz, C. (2003) Endothelial and nonendothelial sources of PDGF-B regulate pericyte recruitment and influence vascular pattern formation in tumors. The Journal of Clinical Investigation, 112, 1142-1151.
2. Anagnostou, A., Liu, Z., Steiner, M., Chin, K., Lee, E.S., Kessimian, N. & Noguchi, C.T. (1994) Erythropoietin receptor mRNA expression in human endothelial cells. Proceedings of the National Academy of Sciences of the United States of America, 91, 3974-3978.
3. Arcasoy, M.O., Jiang, X. & Haroon, Z.A. (2003) Expression of erythropoietin receptor splice variants in human cancer. Biochemical and Biophysical Research Communications, 307, 999-1007.
4. Brown, W.M., Maxwell, P., Graham, A.N., Yakkundi, A., Dunlop, E.A., Shi, Z., Johnston, P.G. & Lappin, T.R. (2007) Erythropoietin receptor expression in non-small cell lung carcinoma: a question of antibody specificity. Stem Cells, 25, 718-722.
5. Broxmeyer, H.E. (2013) Erythropoietin: multiple targets, actions, and modifying influences for biological and clinical consideration. Journal of Experimental Medicine, 210, 205-208.
6. Caro, J.J., Salas, M., Ward, A. & Goss, G. (2001) Anemia as an independent prognostic factor for survival in patients with cancer: a systemic, quantitative review. Cancer, 91, 2214-2221.
7. Elliott, S., Busse, L., Bass, M.B., Lu, H., Sarosi, I., Sinclair, A.M., Spahr, C., Um, M., Van, G. & Begley, C.G. (2006) Anti-Epo receptor antibodies do not predict Epo receptor expression. Blood, 107, 1892-1895.
8. Elliott, S., Swift, S., Busse, L., Scully, S., Van, G., Rossi, J. & Johnson, C. (2013) Epo receptors are not detectable in primary human tumor tissue samples. PLoS One, 8, e68083.
9. Ghezzi, P., Bernaudin, M., Bianchi, R., Blomgren, K., Brines, M., Campana, W., Cavaletti, G., Cerami, A., Chopp, M., Coleman, T., Digicaylioglu, M., Ehrenreich, H., Erbayraktar, S., Erbayraktar, Z., Gassmann, M., Genc, S., Gokmen, N., Grasso, G., Juul, S., Lipton, S.A., Hand, C.C., Latini, R., Lauria, G., Leist, M., Newton, S.S., Petit, E., Probert, L., Sfacteria, A., Siren, A.L., Talan, M., Thiemermann, C., Westenbrink, D., Yaqoob, M. & Zhu, C. (2010) Erythropoietin: not just about erythropoiesis. Lancet, 375, 2142.
10. Graham, F.L. & van der Eb, A.J. (1973) A new technique for the assay of infectivity of human adenovirus 5 DNA. Virology, 52, 456-467.
11. Gross, M., Ben-Califa, N., McMullin, M.F., Percy, M.J., Bento, C., Cario, H., Minkov, M. & Neumann, D. (2014) Polycythaemia-inducing mutations in the erythropoietin receptor (EPOR): mechanism and function as elucidated by epidermal growth factor receptor-EPOR chimeras. British Journal of Haematology, 165, 519-528.
12. Henke, M., Laszig, R., Rube, C., Schafer, U., Haase, K.D., Schilcher, B., Mose, S., Beer, K.T., Burger, U., Dougherty, C. & Frommhold, H. (2003) Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet, 362, 1255-1260.
13. Hill, J.W., Cong, Z., Hess, G., McGarvey, N. & Nordyke, R.J. (2012) Hemoglobin decline in chemotherapy patients prior to and after policy changes affecting use of erythropoiesis-stimulating agents: 2006-2009. Journal of International Medical Research, 40, 1532-1545.
14. Jelkmann, W. (2010) Erythropoietin: back to basics. Blood, 115, 4151-4152.
15. Katz, O., Gil, L., Lifshitz, L., Prutchi-Sagiv, S., Gassmann, M., Mittelman, M. & Neumann, D. (2007) Erythropoietin enhances immune responses in mice. European Journal of Immunology, 37, 1584-1593.
16. Lappin, T.R., Maxwell, A.P. & Johnston, P.G. (2002) EPO's alter ego: erythropoietin has multiple actions. Stem Cells, 20, 485-492.
17. Leyland-Jones, B., Semiglazov, V., Pawlicki, M., Pienkowski, T., Tjulandin, S., Manikhas, G., Makhson, A., Roth, A., Dodwell, D., Baselga, J., Biakhov, M., Valuckas, K., Voznyi, E., Liu, X. & Vercammen, E. (2005) Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study. Journal of Clinical Oncology, 23, 5960-5972.
18. Liang, K., Esteva, F.J., Albarracin, C., Stemke-Hale, K., Lu, Y., Bianchini, G., Yang, C.Y., Li, Y., Li, X., Chen, C.T., Mills, G.B., Hortobagyi, G.N., Mendelsohn, J., Hung, M.C. & Fan, Z. (2010) Recombinant human erythropoietin antagonizes trastuzumab treatment of breast cancer cells via Jak2-mediated Src activation and PTEN inactivation. Cancer Cell, 18, 423-435.
19. Lifshitz, L., Tabak, G., Gassmann, M., Mittelman, M. & Neumann, D. (2010) Macrophages as novel target cells for erythropoietin. Haematologica, 95, 1823-1831.
20. Mausberg, A.K., Meyer, Zu., Horste, G., Dehmel, T., Stettner, M., Lehmann, H.C., Sheikh, K.A. & Kieseier, B.C. (2011) Erythropoietin ameliorates rat experimental autoimmune neuritis by inducing transforming growth factor-beta in macrophages. PLoS One, 6, e26280.
21. Miller, C.P., Lowe, K.A., Valliant-Saunders, K., Kaiser, J.F., Mattern, D., Urban, N., Henke, M. & Blau, C.A. (2009) Evaluating erythropoietin-associated tumor progression using archival tissues from a phase III clinical trial. Stem Cells, 27, 2353-2361.
22. Mittelman, M., Zeidman, A., Kanter, P., Katz, O., Oster, H., Rund, D. & Neumann, D. (2004) Erythropoietin has an anti-myeloma effect - a hypothesis based on a clinical observation supported by animal studies. European Journal of Haematology, 72, 155-165.
23. Nairz, M., Sonnweber, T., Schroll, A., Theurl, I. & Weiss, G. (2012) The pleiotropic effects of erythropoietin in infection and inflammation. Microbes and Infection, 14, 238-246.
24. Oster, H.S., Prutchi-Sagiv, S., Halutz, O., Shabtai, E., Hoffman, M., Neumann, D. & Mittelman, M. (2013) Erythropoietin treatment is associated with an augmented immune response to the influenza vaccine in hematologic patients. Experimental Hematology, 41, 167-171.
25. Provatopoulou, S.T. & Ziroyiannis, P.N. (2011) Clinical use of erythropoietin in chronic kidney disease: outcomes and future prospects. Hippokratia, 15, 109-115.
26. Prutchi-Sagiv, S., Golishevsky, N., Oster, H.S., Katz, O., Cohen, A., Naparstek, E., Neumann, D. & Mittelman, M. (2006) Erythropoietin treatment in advanced multiple myeloma is associated with improved immunological functions: could it be beneficial in early disease? British Journal of Haematology, 135, 660-672.
27. Prutchi-Sagiv, S., Lifshitz, L., Orkin, R., Mittelman, M. & Neumann, D. (2008) Erythropoietin effects on dendritic cells: potential mediators in its function as an immunomodulator? Experimental Hematology, 36, 1682-1690.
28. Rizzo, J.D., Brouwers, M., Hurley, P., Seidenfeld, J., Arcasoy, M.O., Spivak, J.L., Bennett, C.L., Bohlius, J., Evanchuk, D., Goode, M.J., Jakubowski, A.A., Regan, D.H. & Somerfield, M.R. (2010) American Society of Hematology/American Society of Clinical Oncology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer. Blood, 116, 4045-4059.
29. Smith, K.J., Bleyer, A.J., Little, W.C. & Sane, D.C. (2003) The cardiovascular effects of erythropoietin. Cardiovascular Research, 59, 538-548.
30. Stasko, J., Drouet, L., Soria, C., Mazoyer, E., Caen, J. & Kubisz, P. (2002) Erythropoietin and granulocyte colony-stimulating factor increase plasminogen activator inhibitor-1 release in HUVEC culture. Thrombosis Research, 105, 161-164.
31. Trincavelli, M.L., Da Pozzo, E., Ciampi, O., Cuboni, S., Daniele, S., Abbracchio, M.P. & Martini, C. (2013) Regulation of erythropoietin receptor activity in endothelial cells by different erythropoietin (EPO) derivatives: an in vitro study. International Journal of Molecular Sciences, 14, 2258-2281.
32. Vogel, J. & Gassmann, M. (2011) Erythropoietic and non-erythropoietic functions of erythropoietin in mouse models. Journal of Physiology, 589, 1259-1264.
33. Wenger, R.H. & Kurtz, A. (2011) Erythropoietin. Comprehensive Physiology, 1, 1759-1794.
34. Xue, Y., Lim, S., Yang, Y., Wang, Z., Jensen, L.D., Hedlund, E.M., Andersson, P., Sasahara, M., Larsson, O., Galter, D., Cao, R., Hosaka, K. & Cao, Y. (2012) PDGF-BB modulates hematopoiesis and tumor angiogenesis by inducing erythropoietin production in stromal cells. Nature Medicine, 18, 100-110.